Beam Therapeutics Inc. (BEAM) Operating Margin
- Operating margin · 12 months: Value -242.27%; Formula and calculation Operating income / revenue. Period ending 2026-06-30..
Operating margin
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Operating margin · 12 months | -242.27% | Operating income / revenue. Period ending 2026-06-30. $-378.02M ÷ $156.03M × 100 ≈ -242.27% |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Operating income | -378.02M USD | Operating Income (Loss) |
| Revenue | 156.03M USD | Revenue from Contract with Customer, Excluding Assessed Tax |
| Cost of products and services | (m) | |
| Research and development | 408.66M USD | Research and Development Expense |
| Selling, general and administration | (m) |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Operating income (USD) | Revenue (USD) | Cost of products and services (USD) | Research and development (USD) | Selling, general and administration (USD) | Operating margin |
|---|---|---|---|---|---|---|
| 2026-06-30 | $-378.02M | $156.03M | (m) | $408.66M | (m) | -242.27% |
| 2026-03-31 | $-371.62M | $164.01M | (m) | $415.33M | (m) | -226.58% |
| 2025-12-31 | $-383.69M | $139.74M | (m) | $409.62M | (m) | -274.57% |
| 2025-09-30 | $-466.29M | $55.70M | (m) | $411.79M | (m) | -837.12% |
| 2025-06-30 | $-445.98M | $60.27M | (m) | $396.28M | (m) | -739.94% |
| 2025-03-31 | $-430.72M | $63.58M | (m) | $381.56M | (m) | -677.47% |
| 2024-12-31 | $-415.57M | $63.52M | (m) | $367.56M | (m) | -654.25% |
| 2024-09-30 | $-182.67M | $349.64M | (m) | $406.19M | (m) | -52.25% |
| 2024-06-30 | $-184.44M | $352.57M | (m) | $411.99M | (m) | -52.31% |
| 2024-03-31 | $-181.69M | $360.91M | (m) | $422.55M | (m) | -50.34% |
| 2023-12-31 | $-176.49M | $377.71M | (m) | $437.38M | (m) | -46.73% |
| 2023-09-30 | $-398.33M | $81.55M | (m) | $383.64M | (m) | -488.42% |
| 2023-06-30 | $-381.36M | $80.16M | (m) | $368.88M | (m) | -475.75% |
| 2023-03-31 | $-361.18M | $76.70M | (m) | $345.83M | (m) | -470.93% |
| 2022-12-31 | $-338.48M | $60.92M | (m) | $311.59M | (m) | -555.61% |
| 2022-09-30 | $-312.98M | $91.95M | (m) | $322.03M | (m) | -340.37% |
| 2022-06-30 | $-291.31M | $76.92M | (m) | $291.37M | (m) | -378.74% |
| 2022-03-31 | $-268.32M | $60.27M | (m) | $262.39M | (m) | -445.19% |
| 2021-12-31 | $-392.46M | $51.84M | (m) | $387.09M | (m) | -757.01% |
| 2021-09-30 | $-369.78M | $781.00K | (m) | $322.76M | (m) | -47346.99% |
| 2021-06-30 | $-337.47M | $24.00K | (m) | $297.96M | (m) | -1406112.50% |
| 2021-03-31 | $-304.78M | $24.00K | (m) | $271.74M | (m) | -1269908.33% |
| 2020-12-31 | $-132.76M | $24.00K | (m) | $103.18M | (m) | -553166.67% |
| 2020-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | $-75.15M | $18.00K | (m) | $54.62M | (m) | -417522.22% |
| 2019-09-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-03-31 | (m) | (m) | (m) | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |